Literature DB >> 2973433

gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.

E Fischer1, M A Ouaissi, P Velge, J Cornette, M D Kazatchkine.   

Abstract

A glycoprotein of apparent molecular weight 58,000 (unreduced)/68,000 (in its reduced form) (gp 58/68), which is one of the fibronectin/collagen receptors of Trypanosoma cruzi, was purified to homogeneity from the trypomastigote forms of the Tehuantepec and Y strains of the parasite. Purified gp 58/68 inhibited formation of cell-bound and fluid-phase alternative pathway C3 convertase in a dose-dependent fashion, as assessed using purified human complement components. Gp 58/68 differed from the human regulatory proteins H, DAF, MCP and CR1 and from previously reported regulatory proteins on the parasite membrane in that it was unable to enhance decay-dissociation of preformed alternative pathway C3 convertase sites, did not serve as a co-factor for I-mediated cleavage of C3b and had no inhibitory activity on the classical pathway convertases. The inhibitory effect of gp 58/68 was most likely dependent on an interaction of the protein with factor B rather than with C3b. Gp 58/68 provides trypomastigotes with an additional potential mechanism for escaping complement lysis by the human alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973433      PMCID: PMC1384928     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Purification of C3b inactivator and demonstration of its two polypeptide chain structure.

Authors:  D T Fearon
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

2.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

Authors:  J H Morrissey
Journal:  Anal Biochem       Date:  1981-11-01       Impact factor: 3.365

3.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

4.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

5.  Effect of Trypanosoma cruzi membrane components on the formation of the classical pathway C3 convertase.

Authors:  T L Kipnis; D V Tambourgi; M Sucupira; W Dias-da-Silva
Journal:  Braz J Med Biol Res       Date:  1986       Impact factor: 2.590

6.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

7.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

8.  Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages.

Authors:  T L Kipnis; J R David; C A Alper; A Sher; W D da Silva
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

9.  Studies on the selective lysis and purification of Trypanosoma cruzi.

Authors:  N Nogueira; C Bianco; Z Cohn
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

10.  Complement receptor is an inhibitor of the complement cascade.

Authors:  K Iida; V Nussenzweig
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Complement evasion by parasites: search for "Achilles' heel".

Authors:  Z Fishelson
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance.

Authors:  K A Norris
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 3.  Carbohydrate immunity in American trypanosomiasis.

Authors:  L R Travassos; I C Almeida
Journal:  Springer Semin Immunopathol       Date:  1993

Review 4.  Complement-related proteins in pathogenic organisms.

Authors:  Z Fishelson
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Identification of the gene family encoding the 160-kilodalton Trypanosoma cruzi complement regulatory protein.

Authors:  K A Norris; J E Schrimpf; M J Szabo
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

6.  Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.

Authors:  Christian Emerson Rosas-Jorquera; Luiz Roberto Sardinha; Fernando Delgado Pretel; André Luis Bombeiro; Maria Regina D'Império Lima; José Maria Alvarez
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

7.  Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies.

Authors:  K A Norris; G Harth; M So
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

8.  Cellular response to Trypanosoma cruzi infection induces secretion of defensin α-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection.

Authors:  Candice A Johnson; Girish Rachakonda; Yuliya Y Kleshchenko; Pius N Nde; M Nia Madison; Siddharth Pratap; Tatiana C Cardenas; Chase Taylor; Maria F Lima; Fernando Villalta
Journal:  Infect Immun       Date:  2013-08-26       Impact factor: 3.441

9.  Biochemical analysis of the membrane and soluble forms of the complement regulatory protein of Trypanosoma cruzi.

Authors:  K A Norris; J E Schrimpf
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  A lytic monoclonal antibody to Trypanosoma cruzi bloodstream trypomastigotes which recognizes an epitope expressed in tissues affected in Chagas' disease.

Authors:  N W Zwirner; E L Malchiodi; M G Chiaramonte; C A Fossati
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.